Evidence-centered rules issued in 2014 because of the American Academy of Neurology concluded that nabiximols is most likely effective for enhancing subjective spasticity signs and symptoms, most likely ineffective for reducing goal spasticity measures or bladder incontinence, And perhaps ineffe